- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04421378
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted in 2 phases: a Phase 1a dose finding study followed by Phase 1b (dose expansion) and a Phase 2 randomized efficacy exploration study and will independently evaluate 3 different combination regimens in 3 treatment arms in patients with nGBM (Arms A and B) or with rGBM (Arm C).
- Arm A: evaluating the combination of selinexor with radiation therapy (S-RT) in nGBM participants with uMGMT
- Arm B: evaluating the combination of selinexor with radiation therapy and temozolomide (TMZ) (S-TRT) in nGBM participants with methylated-O6-methylguanine-DNA-methyltransferase (mMGMT)
- Arm C: evaluating the combination of selinexor with lomustine (or carmustine, if lomustine is not available) (S-L/C) in rGBM participants regardless of MGMT status
- Arm D: evaluating the combination of selinexor with bevacizumab in rGBM participants regardless of MGMT status
- Arm E: evaluating the combination of selinexor with tumor treating fields (TTField) in rGBM participants regardless of MGMT status
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2MG
- Princess Margaret Hospital (PMH)
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center)
-
San Francisco, California, United States, 94122
- University of California
-
-
Florida
-
Miami, Florida, United States, 33176
- Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Piedmont Healthcare
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Feinberg School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack Meridian Health, 92 Second Street
-
Morristown, New Jersey, United States, 07960
- Atlantic Health Systems Hospital Corp.
-
-
New York
-
Lake Success, New York, United States, 11042
- Northwell Health
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
New York, New York, United States, 10075
- Lenox Hill Hospital-Northwell Health
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- University of Utah - Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington - Alvord Brain Tumor Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Written informed consent in accordance with federal, local, and institutional guidelines.
- Age ≥18 years at the time of informed consent and ≥22 year for Arm E.
- Pathologically confirmed glioblastoma (including all histological variants; documentation to be provided) that are newly diagnosed (for Arms A and B) or relapsed disease (for Arm C, D and E) after 1 to 2 line of systemic therapy (RT ± TMZ or RT ± TMZ in combination with other drug) (surgical resection of recurrent disease allowed). For Arms A and B, MGMT status should be available.
Prior therapy:
- Arms A and B: participants who have not received RT or any systemic therapy for brain tumor and must be eligible for definitive external beam RT and TMZ
- Arm C, D and E: participants must have received prior treatment with RT with or without TMZ and only 1 prior line of therapy (RT ± TMZ in combination with other drug is allowed).
- Measurable disease according to RANO/modified RANO guidelines is required only for Arm C, D and E; it is not required for Arms A or B.
- Participants enrolling into Arms C, D, and E must be on a stable or decreasing dose of corticosteroids (or none) for at least 5 days prior to the baseline magnetic resonance imaging (MRI).
- Karnofsky Performance Score (KPS) ≥70 (for Arms A and B) and 60 (for Arms C, D, and E).
Participants must have adequate organ function ≤2 weeks of study treatment as defined by the following laboratory criteria:
- Hematological function ≤7 days prior to Cycle 1 Day 1 (C1 D1): Absolute neutrophil count (ANC) ≥1.5*10^9 per Liter (/L); platelet count ≥150*10^9/L; and hemoglobin (Hb) ≥10.0 gram per deciliter (g/dL). Transfusion is not allowed within 7 days prior to C1 D1
- Hepatic function: bilirubin ≤2*the upper limit of normal (ULN), alanine transaminase (ALT) ≤2.5*ULN, aspartate transaminase (AST) ≤2.5*ULN; unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin must be <4*ULN
- Renal function: calculated (Cockcroft-Gault) or measured creatinine clearance ≥30 milliliter per minute (mL/min)
- Female participants of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 6 months following the last dose of study treatment.
- Fertile male participants who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 6 months following the last dose of study treatment.
- For Arms A and B: participants must have had surgery and/or biopsy not greater than [>] 8 weeks prior to initial screening.
- Participants must consent to provide tumor tissue and blood samples to be used for future molecular testing for correlative studies.
- Limited to supratentorial disease for Arm E only.
Exclusion Criteria
- Participants who are receiving any other investigational agents and /or have had prior therapy including:
For Arms A and B only:
- Participants who have previously received RT to the brain
- Participants who received chemotherapy for the treatment of their glioma
Participants who are being treated with implanted Gliadel wafers
For Arm C:
Prior nitrosoureas
For Arms C, D, and E:
- <4 weeks from prior TMZ or other chemotherapy, or <4 weeks or 5 half-lives (whichever is shorter) for investigational agents prior to start of study treatment
- Prior treatment bevacizumab or other direct Vascular endothelial growth factor/Vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors. For any questions of the definition of a direct VEGF/VEGFR inhibitor, consult the study Medical Monitor
Any AE which has not recovered to Grade <=1, or returned to baseline, related to the previous GBM therapy, except alopecia, and some other Grade 2 AEs that have been stabilized (upon Medical Monitor approval)
- Participants who are being treated or plan to be treated during this study with TTField for participants in Arms A to D.
- Major surgery <2 weeks prior to the start of study treatment for Arms A to C and E, <4 weeks for Arm D.
- History of allergic reactions attributed to compounds of similar chemical or biological composition to selinexor or other study treatment.
- Participants must not have significantly diseased or obstructed gastrointestinal tract malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medication.
- Participants with coagulation problems and medically significant bleeding in the month prior to start of treatment (peptic ulcers, epistaxis, intracranial hemorrhage, spontaneous bleeding). Prior history of deep vein thrombosis or pulmonary embolism is not exclusionary.
- Currently pregnant or breastfeeding.
- For Arms A and B: participants with pre-existing known or suspected radiation sensitivity syndromes will be excluded due to potential confounding effect on outcome.
- Any life-threatening illness, active medical condition, organ system dysfunction, or serious active psychiatric issue which, in the Investigator's opinion, could compromise the participant's safety or the participant's ability to remain compliant with study procedures.
- Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable even if parenteral.
- Participants with mutated isocitrate dehydrogenase (IDH) should be excluded for Phase 2.
- For participants in Arm C, Forced Vital Capacity (FVC) or Carbon Monoxide Diffusing Capacity (DLCO) below 70% of predicted.
- For Arm E: implanted active electronic medical devices such as programmable intraventricular shunts, spinal cord, vagus nerve or deep brain stimulators, pacemakers or implantable automatic defibrillators, skull defect (i.e. missing bone with no replacement), sensitivity to conductive hydrogels as used in electrocardiograms (ECGs), an underlying serious scalp condition that may interfere with placement of arrays, or bullet fragments, or documented clinically significant arrhythmias.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1: Arm A: Selinexor+Radiation Therapy
Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.
|
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Other Names:
Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
|
Active Comparator: Arm A Control: Temozolomide+Radiation Therapy
Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.
|
Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
Other Names:
|
Experimental: Phase 1: Arm B: Selinexor+Temozolomide+Radiation Therapy
Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period.
Participants will continue selinexor weekly per dose level assigned until PD.
|
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Other Names:
Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
Other Names:
|
Active Comparator: Arm B Control: Temozolomide+Radiation Therapy
Participants with nGBM mMGMT will receive 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.
|
Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
Other Names:
|
Experimental: Arm C: Selinexor+Lomustine/Carmustine
Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m^2 of lomustine or 150-200 mg/m^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
|
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Other Names:
Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
Dose and Formulation: 150 or 200 mg/m^2; Route of Administration: Intravenous
|
Active Comparator: Arm C Control: Lomustine/Carmustine
Participants with rGBM uMGMT or mMGMT will receive 110 mg/m^2 of lomustine or 200 mg/m^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
|
Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
Dose and Formulation: 150 or 200 mg/m^2; Route of Administration: Intravenous
|
Experimental: Arm D: Selinexor+Bevacizumab
Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.
|
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Other Names:
Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
|
Experimental: Arm E: Selinexor+TTField
Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
|
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Other Names:
Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase 1a: Maximum Tolerated Dose Per Arm: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Time Frame: During Cycle 1 of treatment (42 days/cycle) for each participant
|
During Cycle 1 of treatment (42 days/cycle) for each participant
|
Phase 1a: Recommended Phase 2 Dose Per Arm
Time Frame: Cycle 1 Day 1 up to 14 days after last dose (42 days/cycle)
|
Cycle 1 Day 1 up to 14 days after last dose (42 days/cycle)
|
Phase 1a: Number of Participants with Adverse Events (AEs) with Grade Greater Than or Equal to (>=) 3, Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
Time Frame: Up to 30 days post last dose
|
Up to 30 days post last dose
|
Phase 1b: Progressive Free Survival at 3 Months for All Arms
Time Frame: 3 Months
|
3 Months
|
Phase 1b: Overall Survival (OS) for All Arms
Time Frame: From date of randomization up to death (Up to 24 months)
|
From date of randomization up to death (Up to 24 months)
|
Phase 2: Progression-free Survival (PFS) in Arms A and B
Time Frame: From date of randomization to the date of disease progression or death (Up to 24 months)
|
From date of randomization to the date of disease progression or death (Up to 24 months)
|
Phase 2: Overall Survival (OS) for Arm C
Time Frame: From date of randomization up to death (Up to 24 months)
|
From date of randomization up to death (Up to 24 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase 1a: Overall Survival (OS) for Each Arm
Time Frame: From first dose of study treatment until death due to any cause (Up to 24 months)
|
From first dose of study treatment until death due to any cause (Up to 24 months)
|
Phase 1a/1b: Time to Progression (TTP) for Each Arm
Time Frame: From first dose of study treatment until progression or death due to progression (Up to 24 months)
|
From first dose of study treatment until progression or death due to progression (Up to 24 months)
|
Phase 1a/1b: Progressive Free Survival (PFS) for Each Arm
Time Frame: From first dose of study treatment until progression or death due to any cause (Up to 24 months)
|
From first dose of study treatment until progression or death due to any cause (Up to 24 months)
|
Phase 1a/1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E
Time Frame: From first dose of study treatment until death due to any cause (Up to 24 months)
|
From first dose of study treatment until death due to any cause (Up to 24 months)
|
Phase 1a/1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology Criteria in Arm C, D and E
Time Frame: From first dose of study treatment until death due to any cause (Up to 24 months)
|
From first dose of study treatment until death due to any cause (Up to 24 months)
|
Phase 1a/1b: Duration of Response (DOR) in Arm C, D and E
Time Frame: From the date of first evidence of objective response until progression (Up to 24 months)
|
From the date of first evidence of objective response until progression (Up to 24 months)
|
Phase 1a/1b: Maximum Plasma Concentration (Cmax) of Selinexor
Time Frame: 2, 4, and 6 hours post-dose
|
2, 4, and 6 hours post-dose
|
Phase 1a/1b: Area Under the Concentration-time Curve (AUC) of Selinexor
Time Frame: 2, 4, and 6 hours post-dose
|
2, 4, and 6 hours post-dose
|
Phase 1a/1b: Apparent Clearance (CL) of Selinexor
Time Frame: 2, 4, and 6 hours post-dose
|
2, 4, and 6 hours post-dose
|
Phase 1b: Number of Participants with Adverse Events (AEs) with Grade Greater Than or Equal to (>=) 3, Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
Time Frame: Up to 30 days post last dose
|
Up to 30 days post last dose
|
Phase 1b: Maximum Tolerated Dose
Time Frame: Up to 24 months
|
Up to 24 months
|
Phase 1b: Recommended Phase 2 Dose
Time Frame: Up to 24 months
|
Up to 24 months
|
Phase 2: Progression Free Survival Per (PFS) as Assessed by Investigator per Modified Response Assessment in Neuro-Oncology Criteria in Arms A and B
Time Frame: From date of randomization to the date of disease progression or death (Up to 24 months)
|
From date of randomization to the date of disease progression or death (Up to 24 months)
|
Phase 2: Overall Survival for Participants With Newly Diagnosed Glioblastoma Multiforme in Arms A and B
Time Frame: From date of randomization to death (Up to 24 months)
|
From date of randomization to death (Up to 24 months)
|
Phase 2: Progression Free Survival (PFS) as Assessed by Independent Review Committee (IRC) per Modified Response Assessment in Neuro-Oncology Criteria in Arm C
Time Frame: From date of randomization to the date of disease progression or death (Up to 24 months)
|
From date of randomization to the date of disease progression or death (Up to 24 months)
|
Phase 2: Progression Free Survival (PFS) as Assessed by Investigator per Modified Response Assessment in Neuro-Oncology Criteria in Arm C
Time Frame: From date of randomization to the date of disease progression or death (Up to 24 months)
|
From date of randomization to the date of disease progression or death (Up to 24 months)
|
Phase 2: Overall Response Rate (ORR) as Assessed by IRC in Arm C
Time Frame: From first dose of study treatment until death due to any cause (Up to 24 months)
|
From first dose of study treatment until death due to any cause (Up to 24 months)
|
Phase 2: Overall Response Rate (ORR) as Assessed by Investigator in Arm C
Time Frame: From first dose of study treatment until death due to any cause (Up to 24 months)
|
From first dose of study treatment until death due to any cause (Up to 24 months)
|
Phase 2: Disease Control Rate (DCR) as Assessed by IRC in Arm C(TEAEs) by Severity Grade ≥3, Serious Adverse event (SAEs), and AEs Leading to Treatment Discontinuation
Time Frame: From first dose of study treatment until death due to any cause (Up to 24 months)
|
From first dose of study treatment until death due to any cause (Up to 24 months)
|
Phase 2: Disease Control Rate (DCR) as Assessed by Investigator in Arm C
Time Frame: From first dose of study treatment until death due to any cause (Up to 24 months)
|
From first dose of study treatment until death due to any cause (Up to 24 months)
|
Phase 2: Duration of Response (DOR) as Assessed by IRC in Arm C
Time Frame: From the date of first evidence of objective response until progression (Up to 24 months)
|
From the date of first evidence of objective response until progression (Up to 24 months)
|
Phase 2: Duration of Response (DOR) as Assessed by Investigator in Arm C
Time Frame: From the date of first evidence of objective response until progression (Up to 24 months)
|
From the date of first evidence of objective response until progression (Up to 24 months)
|
Phase 2: Progression Free Survival at 6 Months (PFS6) as Assessed by IRC in all Arms
Time Frame: 6 Months
|
6 Months
|
Phase 2: Progression Free Survival at 6 Months (PFS6) as Assessed by Investigator in all Arms
Time Frame: 6 Months
|
6 Months
|
Phase 2: Overall Survival Rate at 12 and 24 Months in all Arms
Time Frame: 12 and 24 Months
|
12 and 24 Months
|
Phase 2: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) by Grade >=3, Serious Adverse event (SAEs), and AEs Leading to Treatment Discontinuation
Time Frame: Up to 30 days post last dose
|
Up to 30 days post last dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrew B Lassman, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Temozolomide
- Bevacizumab
- Carmustine
- Lomustine
Other Study ID Numbers
- XPORT-GBM-029
- 2021-000080-67 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Polaris GroupRecruitingGlioblastoma Multiforme (GBM)Taiwan
-
University of IowaEisai Inc.TerminatedPrimary Glioblastoma MultiformeUnited States
-
TVAX BiomedicalFDA Office of Orphan Products DevelopmentRecruitingGlioblastoma Multiforme of BrainUnited States
Clinical Trials on Selinexor
-
Karyopharm Therapeutics IncBelgium and Luxembourg Gynaecological Oncology Group; North-Eastern German... and other collaboratorsActive, not recruitingEndometrial CancerUnited States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Rhabdoid Tumor | Wilms Tumor | Nephroblastoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | XPO1 Gene MutationUnited States
-
The First Hospital of Jilin UniversityRecruitingPTCL Patients Who Achieved Complete Response From Frontline TreatmentChina
-
University of RochesterKaryopharm Therapeutics IncRecruitingSmoldering Multiple MyelomaUnited States
-
Karyopharm Therapeutics IncGOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaboratorsRecruitingEndometrial CancerUnited States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Slovakia, Canada, Hungary, Czechia
-
University of UtahKaryopharm Therapeutics IncActive, not recruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States
-
Karyopharm Therapeutics IncCompletedHematological MalignanciesUnited States, Denmark, Canada
-
Karyopharm Therapeutics IncTerminatedRichter's TransformationUnited States, Germany, United Kingdom, Spain, Poland
-
Morten Mau-SoerensenHospices Civils de Lyon; Gustave Roussy, Cancer Campus, Grand Paris; Institut... and other collaboratorsUnknownThymoma | Advanced Thymic Epithelial TumourDenmark, France
-
Chunrui LiNanjing IASO Biotherapeutics Co.,LtdRecruitingExtramedullary Multiple MyelomaChina